Evidence map›Paper›PMID 26100016›Full record

ArticleMolecular and cellular biology2015

p300 Regulates Liver Functions by Controlling p53 and C/EBP Family Proteins through Multiple Signaling Pathways.

Meghan Breaux, Kyle Lewis, Leila Valanejad, Polina Iakova, Fengju Chen, Qianxing Mo, Estela Medrano, Lubov Timchenko, Nikolai Timchenko

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.Cellular and molecular gastroenterology and hepatology · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Meghan BreauxDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Kyle LewisDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Leila ValanejadDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Polina IakovaDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Fengju ChenDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Qianxing MoDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Estela MedranoDepartment of Pathology and Immunology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Lubov TimchenkoDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Nikolai TimchenkoDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA Nikolai.Timchenko@cchmc.org.
Baylor College of Medicine · USCincinnati Children's Hospital Medical Center · US

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Myotonic Dystrophy Type 2R01AR052791 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI TIMCHENKO, LUBOV T · 2005 to 2015
$3.1M
Role of Age in Liver CancerR01CA159942 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI TIMCHENKO, NIKOLAI A. · 2011 to 2015
$1.6M
Inhibition of GSK3 beta as potential therapy for DM1R21AR064488 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI TIMCHENKO, LUBOV T · 2014 to 2015
$370k
NCI NIH HHS R01 CA159942NCI NIH HHS R01CA159942NIAMS NIH HHS AR052791NIAMS NIH HHS AR064488NIAMS NIH HHS R01 AR052791NIAMS NIH HHS R21 AR064488NIA NIH HHS T32AG00018321NIDDK NIH HHS P30 DK078392NIGMS NIH HHS R01 GM551888
6 · The paper itself

Abstract

The histone acetyltransferase p300 has been implicated in the regulation of liver biology; however, molecular mechanisms of this regulation are not known. In this paper, we examined these mechanisms using transgenic mice expressing a dominant negative p300 molecule (dnp300). While dnp300 mice did not show abnormal growth within 1 year, these mice have many alterations in liver biology and liver functions. We found that the inhibition of p300 leads to the accumulation of heterochromatin foci in the liver of 2-month-old mice. Transcriptome sequencing (RNA-Seq) analysis showed that this inhibition of p300 also causes alterations of gene expression in many signaling pathways, including chromatin remodeling, apoptosis, DNA damage, translation, and activation of the cell cycle. Livers of dnp300 mice have a high rate of proliferation and a much higher rate of proliferation after partial hepatectomy. We found that livers of dnp300 mice are resistant to CCl4-mediated injury and have reduced apoptosis but have increased proliferation after injury. Underlying mechanisms of resistance to liver injury and increased proliferation in dnp300 mice include ubiquitin-proteasome-mediated degradation of C/EBPα and translational repression of the p53 protein by the CUGBP1-eukaryotic initiation factor 2 (eIF2) repressor complex. Our data demonstrate that p300 regulates a number of critical signaling pathways that control liver functions.

Indexed as

AnimalsApoptosisCarbon Tetrachloride PoisoningCCAAT-Enhancer-Binding ProteinsCELF1 ProteinCell CycleCell Cycle ProteinsCell ProliferationDNA DamageE1A-Associated p300 ProteinEukaryotic Initiation Factor-2Fatty LiverGene Expression ProfilingGene Expression RegulationHepatocytesHeterochromatinCCAAT-Enhancer-Binding ProteinsCEBPA protein, mouseCELF1 ProteinCELF1 protein, mouseCell Cycle ProteinsE1A-Associated p300 ProteinEp300 protein, mouseEukaryotic Initiation Factor-2HeterochromatinRNA-Binding ProteinsTumor Suppressor Protein p53

Identifiers

PMID26100016
PMCPMC4525310
OpenAlexW2110075937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.